Business Description
Ginkgo Bioworks Holdings Inc
NAICS : 541714
SIC : 8071
ISIN : US37611X1000
Total Employee Number:
485Description
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.75 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.96 | |||||
Debt-to-EBITDA | -1.66 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -8.96 | |||||
Beneish M-Score | -3.27 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.4 | |||||
3-Year EBITDA Growth Rate | 54.7 | |||||
3-Year EPS without NRI Growth Rate | 54 | |||||
3-Year FCF Growth Rate | 23.7 | |||||
3-Year Book Growth Rate | -38 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.08 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 0.21 | |||||
14-Day RSI | 1.43 | |||||
3-1 Month Momentum % | 13.33 | |||||
6-1 Month Momentum % | -3.48 | |||||
12-1 Month Momentum % | -28.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.57 | |||||
Quick Ratio | 4.57 | |||||
Cash Ratio | 4.15 | |||||
Days Sales Outstanding | 65.54 | |||||
Days Payable | 170.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.2 | |||||
Shareholder Yield % | 5.45 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.72 | |||||
Operating Margin % | -257.67 | |||||
Net Margin % | -259.96 | |||||
EBITDA Margin % | -218.06 | |||||
FCF Margin % | -147.53 | |||||
OCF Margin % | -144.08 | |||||
ROE % | -57.14 | |||||
ROA % | -26.14 | |||||
ROIC % | -41.38 | |||||
3-Year ROIIC % | -380.99 | |||||
ROC (Joel Greenblatt) % | -56.06 | |||||
ROCE % | -29.2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.49 | |||||
PB Ratio | 1.02 | |||||
Price-to-Tangible-Book | 1.14 | |||||
EV-to-EBIT | -1.94 | |||||
EV-to-EBITDA | -2.36 | |||||
EV-to-Revenue | 5.16 | |||||
EV-to-FCF | -3.18 | |||||
Price-to-GF-Value | 1.32 | |||||
Earnings Yield (Greenblatt) % | -51.48 | |||||
FCF Yield % | -36.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ginkgo Bioworks Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 2,027.438 | ||
| EPS (TTM) (MXN) | -97.994 | ||
| Beta | 0.9676 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 50.91 | ||
| 14-Day RSI | 1.43 | ||
| 14-Day ATR (MXN) | 1.973406 | ||
| 20-Day SMA (MXN) | 143.5 | ||
| 12-1 Month Momentum % | -28.27 | ||
| 52-Week Range (MXN) | 117 - 289 | ||
| Shares Outstanding (Mil) | 67.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ginkgo Bioworks Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ginkgo Bioworks Holdings Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 164 days | ||
| Annual report for 2026 | 2027-02-26 | In 163 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 163 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 52 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 51 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 170.00 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 170.00 (+0.00%) | ||
| General meeting for 2026 | 2026-06-11 08:00 | 150.00 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 176.13 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 176.13 (+0.00%) |
Show
Entries
Ginkgo Bioworks Holdings Inc Frequently Asked Questions
What is Ginkgo Bioworks Holdings Inc(MEX:DNA)'s stock price today?
The current price of MEX:DNA is MXN117.00. The 52 week high of MEX:DNA is MXN289.00 and 52 week low is MXN117.00.
When is next earnings date of Ginkgo Bioworks Holdings Inc(MEX:DNA)?
The next earnings date of Ginkgo Bioworks Holdings Inc(MEX:DNA) is 2026-11-06 Est..
Does Ginkgo Bioworks Holdings Inc(MEX:DNA) pay dividends? If so, how much?
Ginkgo Bioworks Holdings Inc(MEX:DNA) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers